A pharmaceutical composition containing a compound of Formula (I) for treating an opioid receptor-associated condition. Also disclosed is a method for treating an opioid receptor-associated condition using such a compound. Further disclosed are two sets of thiazolidinone compounds of formula (I) : (i) compounds each having an enantiomeric excess greater than 90% and (ii) compounds each being substituted with deuterium.